MedTrace Logo

The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab

NCT02130973 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-08-31

No results posted yet for this study

Summary

This is a three-year study to evaluate the effect of sequential therapy of Forteo (teriparatide) and denosumab on bone density at the spine, hip, leg and forearm.

Conditions

Interventions

DRUG

Standard Clinical Practice Regimen

Standard Clinical Practice Regimen

DRUG

Experimental Cyclic Regimen

Experimental Cyclic Regimen

Sponsors & Collaborators

  • Health Research, Inc.

    lead OTHER

Principal Investigators

  • Felicia Cosman, M.D. · Helen Hayes Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2018-08-31
Completion
2018-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02130973 on ClinicalTrials.gov